Mill to Bill, good luck on your short. You will be successful to short to 28 the charts look right at a probability 50%..
But your lies are despicable.. Greed is running your life... quit the lies.. quit twisting facts..
Once the first good report on any of the Phase 3 comes out. bammm 73 will be a past memory...
Once this becomes a legal prescribed medication (in which I have no doubt it will) I will be the first to sign up with a doctor for my conditions.
lolz... whatev dude... idk about all that... i only care about what your cover is gonna look like
of course, i think youre full of @#it... but if you are covering 12k more shares i think what they call a "short squeeze" is coming
New report shows evaluation by Edison as being 55-58. Sativex CONCEPT alone is worth 18 dollars a share. Sequential pipelines offer upside potential.
Main quote from article:
"LONDON, Dec. 10, 2013 /PRNewswire via COMTEX/ -- Edison's ADR outlook note, Orphan opportunities, highlights that 2014 could be transformative for GW as its pipeline delivers important clinical milestones. GW's acceleration of orphan programmes in childhood epilepsy (Epidiolex) and primary brain cancer (thc:CBD combination) should generate clinical data and Phase II starts for both indications. In addition, the company's lead programme, Sativex, is approaching key value inflection points including Phase III cancer pain data (Q414) and the US Phase III start in MS spasticity (H214).
Edison's healthcare team forecasts peak sales for Epidiolex in Dravet syndrome (DS) of $288m, THC/CBD (GBM) of $246m and GWP42004 (type 2 diabetes) of $1,025m. It projects Sativex peak sales potential of $814m - MS Spasticity at $278m (US $176m, ex-US $102m) and cancer pain at $536m (US $350m, ex-US $186m).
Edison's revised DCF valuation is $715m, or $48.30 per ADR, following the inclusion of R&D pipeline programmes. Positive data from physician-led studies of Epidiolex (mid-2014 onwards) would see the DCF rise to $818m or $55.30/ADR. Positive Sativex Phase III data in cancer pain (late 2014) would see the DCF rise further to $867m or $58.60/ADR. GW's remaining R&D programmes (epilepsy, ulcerative colitis and schizophrenia) offer pure upside to Edison's valuation."